John Libbey Eurotext




PARP inhibitors and breast cancer: update and perspectives
Bulletin du Cancer. Volume 99, Number 4, 441-51, Avril 2012, Synthèse
Résumé Texte intégral
Author(s) : Anthony Gonçalves
Summary : Poly(ADP-ribose) polymerase (PARP) family has become a promising therapeutic target in various malignancies including breast cancer. When homologous recombination repair is deficient, as it is observed in BRCA1/2-mutated tumor models, inhibition of PARP was shown to induce massive and selective tumor cell death (the so-called “synthetic lethality”). In breast cancer, PARP inhibitors have been developed as single-agent in BRCA1/2-mutated tumors or in combination with chemotherapy. Recently, a randomized phase III clinical trial failed to demonstrate any survival improvement by combining the iPARP iniparib to chemotherapy in triple-negative metastatic breast cancer patients. This emphasizes the need for future development of this class of compounds to resolve critical issues such as optimal schedule of administration and association to other anticancer treatments, as well as identification of pertinent biomarkers predictive for efficacy.
Keywords : PARP, breast cancer, BRCA1/2, triple-negative breast cancer

PARP inhibitors and breast cancer: update and perspectives